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Alpha-synuclein aggregates activate calcium pump
SERCA leading to calcium dysregulation
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Abstract
Aggregation of a-synuclein is a hallmark of Parkinson’s disease and
dementia with Lewy bodies. We here investigate the relationship
between cytosolic Ca2+ and a-synuclein aggregation. Analyses of
cell lines and primary culture models of a-synuclein cytopathology
reveal an early phase with reduced cytosolic Ca2+ levels followed
by a later Ca2+ increase. Aggregated but not monomeric
a-synuclein binds to and activates SERCA in vitro, and proximity
ligation assays confirm this interaction in cells. The SERCA inhibitor
cyclopiazonic acid (CPA) normalises both the initial reduction and
the later increase in cytosolic Ca2+. CPA protects the cells against
a-synuclein-aggregate stress and improves viability in cell models
and in Caenorhabditis elegans in vivo. Proximity ligation assays also
reveal an increased interaction between a-synuclein aggregates
and SERCA in human brains affected by dementia with Lewy
bodies. We conclude that a-synuclein aggregates bind SERCA and
stimulate its activity. Reducing SERCA activity is neuroprotective,
indicating that SERCA and down-stream processes may be thera-
peutic targets for treating a-synucleinopathies.
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Introduction
The small unfolded neuronal protein a-synuclein (AS) is closely
linked to Parkinson’s disease (PD). This is evidenced by the findings
that autosomal-dominant familial PD can be caused by duplications
and triplications of the normal SNCA gene encoding AS, by missense
mutations causing exchange of single-amino acid residues (A30P,
E46K, H50Q, G51D and A53T, A53E), and by variations in the SNCA
gene, which represents the greatest genetic risk factor for sporadic
PD. Aggregated amyloid-type fibrillar forms of AS accumulate in
intra-neuronal Lewy body inclusions, which are the pathological
hallmark of PD. Similar AS-containing intracellular inclusions also
exist in other neurodegenerative diseases, so-called a-synucleino-
pathies, that besides PD are dominated by dementia with Lewy
bodies (DLB) and multiple system atrophy (MSA). On the pathway
from native protein to aggregated amyloid species, soluble oligo-
meric species are hypothesised to represent cytotoxic forms. The
molecular mechanisms whereby AS aggregates contribute to the
degeneration of neuronal populations are still unclear, but it has
been proposed that they may be linked to perturbations of homeo-
static mechanisms, for example proteostasis, mitochondrial func-
tions, and direct toxic actions on membranes (reviewed in [1]).
Disturbances in brain Ca2+ regulation have recently been linked
to PD because treatment of hypertension with antagonists of L-type
Ca2+ CaV1 channels reduces the risk of PD [2–4] and the expression
of CaV channels in the brain is changed in PD [4,5]. Average cytoso-
lic Ca2+ concentrations are kept in the nM range, contrasting with
the mM concentrations present outside cells and in the endoplasmic
reticulum. The steep gradient makes Ca2+ an ideal signalling mole-
cule because its cytosolic concentrations can be regulated precisely
with spatio-temporal precision by opening of Ca2+ channels. Once
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in the cytosol, Ca2+ has to be removed by active transporting
pumps in ER, Golgi and the plasma membrane, by Na+/Ca2+
exchanger in the plasma membrane, and by mitochondrial
buffering. The mechanism whereby Ca2+ channel antagonists
modulate the disease course of PD is still unknown, but it is hypoth-
esised that the mechanism reduces the oxidant stress of dopaminer-
gic neurons of substantia nigra that display an energy-consuming
pacemaking firing pattern driven by Ca2+ influx via CaV1 channels
[6]. How this localised effect in dopaminergic neurons is related to
the progressive nature of PD remains unclear, but recent data indi-
cate a complex interplay between AS, cytosolic Ca2+ and CaV1
channels in dopaminergic substantia nigra neurons [7]. Braak
hypothesised that PD arises in the deep brainstem nuclei and
spreads via the midbrain to neocortical regions [8]. This spreading
pattern can be clinically observed in some patients, where REM
sleep behaviour disorder (RBD) represents a prodromal phase of
PD, and most PD patients develop cognitive impairment and demen-
tia in their later phases due to involvement of neocortex.
Ca2+ deregulation has also been hypothesised as playing a
general role in several neurodegenerative diseases like Alzheimer’s
disease and Huntington’s disease. In these diseases, increased
cytosolic Ca2+ represents a common theme which suggests the pres-
ence of mechanisms that lead to the influx of Ca2+ from extracellu-
lar space, endoplasmic reticulum and mitochondria as targets for
therapeutic intervention [9].
We have previously demonstrated that AS aggregate-dependent
degenerative processes are initiated at very early time points in cell
models when no overt phenotypes are present [10]. In the present
study, we investigated the temporal development of changes in
cytosolic Ca2+ in cellular and neuronal models of AS aggregate-
dependent degeneration. Surprisingly, we observed early reduction
in cytosolic Ca2+ across models. This reduction was later followed
by increased cytosolic Ca2+ when degeneration became apparent.
Inhibitors of AS aggregation blocked both the early and late Ca2+
changes. This suggests activation of mechanisms whereby cytosolic
Ca2+ is removed against large gradients. Co-immunoprecipitation
experiments demonstrated that soluble and insoluble AS aggregates
bind to the Ca2+ pump SERCA in contrast to monomers. SERCA is
located in the endoplasmic reticulum. Their interaction was vali-
dated in cells using proximity ligation assays (PLA) where the anti-
body pair against SERCA and AS only produced a signal when the
aggregation was not prevented. In vitro biochemical experiments
demonstrate that AS aggregates activate the transmembrane Ca2+
pumping and ATP hydrolysis by SERCA. Counteracting the activa-
tion of SERCA in cells with the SERCA inhibitor cyclopiazonic acid
(CPA) abrogated both the early reduction and later increase in
cytosolic Ca2+ and protected cells and neurons against AS aggre-
gate-dependent cell death. Treatment of AS-transgenic Caenorhabdi-
tis elegans with CPA protected the dopaminergic neurons against
AS-dependent degeneration. Analyses of human brains by proximity
ligation assay demonstrated the interaction between SERCA and
aggregated AS in patients with DLB but not in controls. Moreover,
SERCA was present in purified Lewy bodies from DLB patients and
in glial cytoplasmic inclusions from MSA patients and SERCA copu-
rified with insoluble AS in the detergent-insoluble fraction of MSA
brain.
We hypothesise that a slow build-up of AS aggregates occurs
within individual neurons during the process of disease spreading
throughout the nervous system. We posit that the accumulating
aggregates in the early stages activate SERCA and cause a reduction
in cytosolic Ca2+, triggering decisive pathophysiological changes
and leading to ensuing cell death (Fig 8). Counteracting this early
phase or its down-stream processes holds promise for increasing the
vitality of the affected cells, thereby slowing and modifying the
disease course.
Results
Neuronal Ca2+ homeostasis has been linked to PD pathogenesis by
virtue of a reduced prevalence of sporadic PD among patients
treated for hypertension with Ca2+-antagonists [2,3] and genome-
wide association studies linking the protective effect of caffeine
against PD to the GRIN2A gene, which encodes a subunit of the
N-methyl-D-aspartate receptor (NMDA)-activated Ca2+ channel
[11,12]. Using the Ca2+ indicator Fura-2, we investigated the tempo-
ral changes in cytosolic Ca2+ concentration in three cell models of
AS aggregation-dependent cytotoxicity, the mitotic oligodendrocytic
cell model OLN-t40-AS, the non-mitotic retinoic acid-differentiated
neuroblastoma SH-SY5Y model with inducible AS expression and
primary hippocampal neuron cultures from mThy1-aSyn (“line 61”)
mice (ASO) overexpressing human AS (Fig 1) [13–15]. The OLN-
t40-AS model revealed a surprising reduction in cytosolic Ca2+ from
approximately 195 to 180 nM when measured 8 h after inducing AS
aggregation by co-expression of the aggregation-inducing protein
p25a (Fig 1A). At this early time point, no overt morphological
changes are observed, but early AS aggregation-dependent gene
expression responses have been detected like increases in the NF-jB
inhibitor, IjBia [10]. Not surprisingly, an increased cytosolic Ca2+
level was measured 24 h after induction of AS aggregation, where
cells show visible degenerative changes such as perinuclear micro-
tubule retraction and nuclear NF-jB translocation (Fig EV4B)
[10,15]. Both the early decrease and later increase in basal intracel-
lular Ca2+ concentration were due to AS aggregation as they could
be inhibited by the AS aggregation inhibitor ASI-1D (Fig 1A) [16].
Differentiated non-mitotic SH-SY5Y cells with inducible AS expres-
sion displayed a reduction of cytosolic Ca2+ from 170 to 150 nM
after 5 days of AS expression and an increase after 10 days when
compared to b-gal-expressing control cells. Aggregate inhibitor ASI-
1D rescued both the initial reduction and late increase (Fig 1B). The
biphasic AS aggregation-dependent cytosolic Ca2+ change also
occurs in primary cultures of mouse hippocampal neurons express-
ing human AS that display a reduction in cytosolic Ca2+ from 150 to
125 nM after 5 days of culture compared to non-transgenic controls
and an increase from 150 to 175 nM after 14 days with both phases
blocked by ASI-1D (Fig 1C). Hence, using different cell models, we
demonstrate a surprising link between early stages of intracellular
AS aggregation and cytosolic Ca2+ reduction. In order to gain more
insight to Ca2+ dynamics upon accumulation of AS, we measured
Ca2+ over time in both the SH-SY5Y model (Fig 1D) and primary
hippocampal neurons (Fig 1E). We found that the early phase of
decreased cytosolic Ca2+ in SH-SY5Y cells is significant from day 4
until day 8, whereas the later Ca2+ increase is pronounced after day
10. This closely resembles what we see in primary hippocampal
neurons where the early phase of reduced Ca2+ is significant
between day 5 and 8 and the later phase, with increased Ca2+
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occurring after day 12 and being significant at day 15 (Fig 1C and E).
The OLN-T40-AS cells, the SH-SY5Y AS cells and primary neurons
isolated from AS-transgenic mice are based on over-expression of
AS but their protein levels of AS are not many fold higher than in
total brain lysate from C57BL/6J wt mice (Fig EV1). In the OLN
model, the AS level is double as high as in brain homogenate and in
the SH-SY5Y model levels after 5 and 10 days of AS expression are
approx. 75 and 150% of total brain homogenate, respectively.
Primary neurons from wt mice have approx. 50% of the AS in adult
mice brain whereas primary neurons from AS-transgenic mice has
approx. 80 and 95% at DIV 5 and DIV 14, respectively.
Toxic AS oligomers associate with ER of presymptomatic AS-
transgenic mice and in brain fractions from PD brain tissue enriched
in ER [17]. The free Ca2+ concentration in the ER is approximately
0.5 mM, compared to a concentration of 100 nM in cytosol [18].
This steep gradient is maintained by the high-capacity transmem-
brane P-type Ca2+ ATPase SERCA and is critical for cellular signal-
ling, for example by inositol-1,4,5 tris-phosphate-activated ER
A
C
B
D E
Figure 1. Cellular stress from AS aggregates causes early reduction in cytosolic calcium followed by later increase.
Cytosolic Ca2+ levels were quantified by the Ca2+ sensor Fura-2 and converted to absolute concentrations using the Fura-2 Calcium Imaging Calibration Kit. The AS
aggregation inhibitor ASI-1D (20 lM) was used to validate that phenotypes were aggregate-dependent. Statistical analyses were performed using one-way ANOVA multiple
comparisons with Sidak post hoc test.
A Mitotic OLN-t40-AS cells were transfected with p25a and the fluorescent transfection marker tdTomato. OLN-t40-AS cells transfected with tdTomato and empty
expression vectors served as negative controls. Bars display Ca2+ concentrations as mean  SD, N = 3 (*P = 0.0001, **P = 0.0002, #P = 0.0011, ##P = 0.0033). The
average Ca2+ level of individual experiments was calculated by measuring > 50 or more tdTomato expressing cells.
B Non-mitotic SH-SY5Y cells were generated by treatment with retinoic acid (RA; 10 lM) for 2 days, after which AS expression was induced by removal of doxycycline
(dox) and cytosolic Ca2+ measured after 5 days and 10 days of AS expression. See timeline under bars. Cells induced to express b-galactosidase (b-gal) upon dox
removal were used as negative controls. Bars display Ca2+ concentrations as mean  SD, N = 4 (*P = 0.0005, **P = 0.0005, #P = 0.0062, ##P = 0.0055). The average
Ca2+ level was calculated by measuring > 200 randomly selected cells in each experiment.
C Primary hippocampal neurons were isolated from new-born (P0) mice expressing human AS under the mThy1 promoter and wild-type (wt) littermates. Cytosolic Ca2+
was measured after 5 days in vitro (5 DIV) and 14 days in vitro culture (14 DIV). See timeline under graphs. Bars display Ca2+ concentrations as mean  SD, N = 3
(*P = 0.002, **P = 0.0007, #P = 0.0071, ##P = 0.0455). The average cellular Ca2+ is based on > 500 neurons per experiment.
D Cytosolic Ca2+ in SHSY5Y cells as in (B) measured every second day. Points represent Ca2+ concentrations as mean  SD, N = 3 (*P = 0.0377, **P = 0.0057,
***P = 0.03, #P = 0.045, ##P = 0.0229).
E Cytosolic Ca2+ in primary hippocampal neurons as in (C) measured every third day. Points represent Ca2+ concentrations as mean  SD, N = 3 (*P = 0.01,
**P = 0.0073, #P = 0.0058).
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channels. Lowering cytosolic Ca2+ requires an active process
whereby Ca2+ is removed from the cytosol against steep gradients.
We hypothesised that the decreased cytosolic Ca2+ was caused by
AS oligomers activating SERCA. To explore this hypothesis, we first
conducted a co-immunoprecipitation experiment to test whether
toxic AS oligomers could bind SERCA. The AS oligomers used as
bait were purified by gel filtration [19,20] and share aggregate-
specific epitopes with AS species in pathological human and mouse
brain tissue and insoluble AS filaments [16,17,21]. Freshly eluted
from the gel filtration column, the oligomers reveal heterogeneous
morphologies in negative stain transmission electron microscopy.
Here, an underlying structure of ribbons with a width of 13 nm form
spirals with a diameter of around 20 nm which further displayed a
tendency to form closed and open circular structures with a diame-
ter of around 40 nm (Fig 2A). As sources for SERCA we used deter-
gent extracts of (i) SERCA2b-rich membrane fractions from mice
brains of C57BL/6 OlaHsd (ASdel) mice, which do not express AS,
to avoid interference from endogenous mouse AS (Fig 2B), and (ii)
SERCA1a-rich rabbit muscle microsomes (Fig EV2A). The extracts
were supplemented with purified recombinant human monomeric
and oligomeric AS (or PBS as negative control) followed by co-
immunoprecipitation using anti-AS IgG conjugated to Sepharose
beads. SERCA displayed preferential binding to oligomeric AS with
negligible binding to monomeric AS irrespective of its source being
muscle or brain (Figs 2B and EV2A). During the pumping cycle,
SERCA exhibits two grossly different conformations, namely a
Ca2+-bound E1 state and a low Ca2+-affinity E2 state. Using 5 lM
Ca2+ or 1 lM of the SERCA inhibitor, thapsigargin, it was possible
to capture SERCA in the E1 and E2 conformations, respectively [22].
Co-immunoprecipitation of the conformation-trapped SERCA, and
AS revealed that AS oligomers bind preferentially to the Ca2+-bound
E1 conformation, although binding to E2 is not completely abolished
(Fig 2C and D). The higher binding to the Ca2+-bound E1 state is
unlikely to be due to Ca2+ interactions with AS because this binding
is of low affinity with a Kd around 0.5 mM [23]. This indicates that
AS oligomer interaction with SERCA displays a high degree of struc-
tural specificity as physiological changes in the SERCA structure are
able to modulate the binding strength.
To test whether SERCA and AS aggregates also interact in a cell
model of AS aggregation-dependent degeneration, we investigated
the SH-SY5Y model with proximity ligation assay using an antibody
pair of rabbit anti-SERCA and mouse anti-AS (Syn211). The cells
were analysed after 5 days of AS expression where they exhibit
reduced cytosolic Ca2+ (Fig 1B). Proximity ligation assay (PLA)
A B
C
D
Figure 2. The endoplasmic reticulum calcium ATPase, SERCA, is an AS oligomer-interacting protein.
A Transmission electron microscopy of freshly isolated oligomers. Arrowheads appoint heterogeneous population of twisted ribbons with a maximum width of 15 nm.
100 nm scale bar is presented.
B Purified AS oligomers (O) and monomers (M) were incubated with detergent extract of ASdel mouse brain before being subjected to co-immunoprecipitation (IP)
using ASY-1 (anti-AS) and non-immune rabbit IgG (NI IgG) coupled to sepharose. PBS was used as additional negative control. 2% input of each sample was used as
input control. The co-IP samples were analysed by immunoblotting anti-SERCA (J15.5) and rabbit polyclonal anti-AS (ASY-1). One representative immunoblot of three
independent experiments is shown.
C The Ca2+-bound E1-state of SERCA was stabilised by 5 lM free Ca2+, and the Ca2+-free E2-state was stabilised by 1 lM thapsigargin. A representative blot of three
replicates is shown.
D Quantification of immunoprecipitation experiments in (C). Bars represent geometric mean  95% CI of SERCA signal relative to the AS signal. N = 3 (Wilcoxon signed
rank test, *P = 0.0382).
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takes advantage of specific secondary antibodies tagged with short,
unique DNA strands, termed PLA probes. When complementary
PLA probes bind to primary antibodies that are in close proximity
(< 40 nm), the DNA strands anneal, allowing enzymatic ligation
and amplification of the signal. Fluorescent complementary oligonu-
cleotide probes then label the amplified DNA sequences. AS-SERCA
PLA of SH-SY5Y cells that have expressed AS for 5 days reveals that
AS is in close proximity with SERCA, as shown by the amplified red
punctate signals (Fig 3A). Inhibiting the formation of AS aggregates
by ASI-1D treatment completely abolishes the interaction of AS and
SERCA (Fig 3B and D), which corroborates the immunoprecipitation
data in Fig 2B of only aggregated AS interacting with SERCA. We
used a competitive ELISA to validate that ASI-1D does not bind the
primary anti-AS antibody Syn211 and thereby artefactually
quenches the PLA signal (Fig EV2B). To further validate the speci-
ficity of the PLA signal, we suppressed AS expression by doxycy-
cline treatment of transgenic SH-SY5Y cells, and this abolished any
PLA signal (Fig 3C and D).
Having demonstrated that AS aggregates can bind SERCA in vitro
and shown that the interaction occurs in AS aggregate-stressed cells,
we wanted to test whether AS oligomers can, indeed, activate
SERCA and thus cause reduction in cytosolic Ca2+ as observed in
AS aggregate-containing cells. First, we investigated the impact on
the enzymatic ATPase activity of SERCA. This measurement
revealed a dose-dependent increase in ATP hydrolysis by SERCA-
containing microsomes when incubated with oligomeric AS in
contrast to monomers (Fig 4A). The activation was not due to an
inherent ATPase activity in AS oligomers as no hydrolysis was
A B
C D
Figure 3. AS aggregates interact with SERCA in SH-SY5Y cells.
Non-mitotic SH-SY5Y cells were grown as depicted in Fig 1B for 5 days after which they were fixed and subjected to proximity ligation assay using Syn211 to target AS and
anti-SERCA2. Representative images are from one experiment of three.
A AS-expressing SH-SY5Y cells were analysed by proximity ligation assay to demonstrate an intracellular interaction between SERCA and AS using SERCA2 and syn211
as antibody pair. Positive PLA signals are shown as red staining merged with the phase contrast image and DAPI-stained nuclei (blue). Scale bar is 20 lm.
B Proximity ligation assays as in (A), but with cells treated with AS aggregation inhibitor, ASI-1d, from day 3. Scale bar is 20 lm.
C Proximity ligation assay as in (B), but in cells without AS expression. Scale bar is 20 lm.
D The signal from proximity ligation assay was quantification as total red fluorescence signal, divided by the DAPI signal to normalise cellular content. In each
experiment, 10 microscopic images containing > 100 cells were quantified. Bars represent mean  SD signal normalised to AS-expressing cells from three
experiments (one-way ANOVA multiple comparisons with Sidak post hoc test, *P = 0.0001).
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Figure 4. AS oligomers activate SERCA’s ATPase activity, calcium pumping and rate of dephosphorylation.
A ATPase activity of SERCA was measured as release of inorganic phosphate from ATP. Sarcoplasmic reticulum (SR) vesicles isolated from rabbit skeletal muscle
containing SERCA1a were mixed with AS oligomer (O), AS monomer (M), b-synuclein (b-syn) or Tau in the presence of ATP (5 mM), Ca2+ (10 lM) and membrane-
permeating ionomycin (2 lM). The ordinate presents ATP hydrolysis within the first 5 min normalised to buffer controls (0 lg/ml). The abscissa presents the
concentration of tested proteins. Bars represent the geometric mean of the relative ATP hydrolysis from three individual experiments  95% CI (Wilcoxon signed rank
test, *P = 0.0482, **P = 0.0034).
B ATPase activity of SERCA was measured as in (A) compared to buffer control (B), but in presence of 50 lg/ml AS monomer (M), oligomer (O), sonicated insoluble fibrils
assembled from full-length 1–140 amino acid wild-type AS (wt PFF), sonicated insoluble fibrils assembled from C-terminally truncated 1–95 amino acid AS (1–95 PFF)
or sonicated insoluble fibrils assembled from islet amyloid polypeptide (IAPP PFF) that represent a control amyloid-type protein aggregate. Bars represent geometric
mean of three individual experiments  95% CI (Kruskal–Wallis one-way rank test with Dunn’s post hoc test, *P = 0.0161, **P = 0.0016).
C Targeting AS oligomer (50 lg/ml) with rabbit polyclonal ASY-1 (1 mg/ml) blocked their ATPase-stimulating activity on SERCA, whereas non-immune rabbit IgG had no
effect. Bars represent the geometric mean of three individual experiments  95% CI compared to buffer controls (Wilcoxon signed rank test, *P = 0.048).
D SERCA-dependent Ca2+ transport across rabbit muscle ER membranes was measured by accumulation of 45Ca2+ in ER vesicles in the presence of 50 lg/ml AS
oligomers (O), monomer (M) or buffer control (B). Ordinate represents accumulation of 45Ca2+ in SR vesicles per min measured as counts per minute (CPM). Columns
represent the geometric mean of three individual experiments  95% CI (Wilcoxon signed rank test, *P = 0.011).
E The effect of AS oligomers on dephosphorylation of the SERCA E1 state. 32P pre-phosphorylated SERCA was incubated with 50 lg/ml oligomer (O), 50 lg/ml monomer
(M) or buffer control in presence of 10 mM EGTA in order to prevent rephosphorylation of SERCA. The residual 32P-SERCA was quantified over time by phospho-
imaging of SERCA isolated by acid SDS–PAGE. Ordinate axis represents percentage remaining 32P phosphorylated SERCA and abscissa represents the time. The
dephosphorylation rate constants were determined to be k = 0.06/s  0.003 for buffer (B), k = 0.04/s  0.003 for monomer (M), and k = 0.10/s  0.006 for oligomer
(O). N = 9 (Kruskal–Wallis one-way rank test with Dunn’s post hoc test, B vs. O: P = 0.0038 and M vs. O: P = 0.0002).
F The effect of AS aggregation on Ca2+ transport into ER in living cells was studied in OLN-t40-AS transfected with low-affinity ER-targeted luminescent aequorin
(erAEQ) and co-expression of p25a to induce aggregation. OLN-93 cells without AS were used as negative control. The transport of Ca2+ into ER was studied 48 h
post-transfection upon supplementing Ca2+-depleted cells with 0.5 mM extracellular Ca2+ by measuring increase in luminescence as ER was refilled with Ca2+. Bars
represent the mean transport rate of Ca2+ into ER  SD. N = 15 (one-way ANOVA multiple comparison with Sidak post hoc test, *P = 0.0001, **P = 0.0023).
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observed when the oligomers were incubated with ATP alone
(Fig EV3A). Moreover, phosphate release was due to Ca2+- and
ATP-dependent mechanisms, ruling out non-specific ATPases and
mobilisation of precipitated phosphate (Fig EV3A). To investigate
the specificity further, we demonstrated that b-synuclein (b-syn)
and Tau proteins had no effect on the ATPase activity of SERCA
(Fig 4A). Insoluble preformed AS filaments (PFF) assembled from
wild-type full-length AS (wt PFF) also activated SERCA, and this
activity was absent in filaments assembled from C-terminally trun-
cated AS (1–95 PFF; Fig 4B). This suggests that activation relies on
folding-specific structures requiring the acidic C-terminus and not
the core amyloid-type beta-sheet structure formed by the N-terminal
95 residues. To further exclude that a common amyloid-type core
structure contributes to SERCA activation, we tested amyloid fibrils
assembled from purified islet amyloid polypeptide (IAPP PFF) and
observed no activation (Fig 4B). To validate that the activation was
not caused by uncharacterised constituents in the preparations, we
pre-incubated AS oligomers with rabbit polyclonal antibody ASY-1
targeting AS, and this treatment blocked stimulation in contrast to
negative control non-immune rabbit IgG (Fig 4C). The above func-
tional studies were conducted on SERCA1a from rabbit muscle
sarcoplasmic reticulum that represents a specialised form of ER, but
AS oligomers could also increase the ATP hydrolysis by cellular ER
microsomes from COS cells overexpressing the human SERCA1a
(Fig EV3B). Second, we studied the effect of AS oligomers on
45Ca2+ uptake into SERCA-containing microsomes to determine
whether increased ATP hydrolysis is due to increased Ca2+ pump-
ing or an uncoupled ATP hydrolysis as reported for thermogenic
drugs [24]. AS oligomers, but not monomers, increase 45Ca2+
uptake compared to the buffer control (Fig 4D).
To exclude that the vesicular 45Ca2+ uptake was due to oligo-
mers making the membrane permeable to Ca2+, we conducted the
following control experiment. First, SERCA1a-containing micro-
somes from rabbit muscles were loaded with 45Ca2+ and treated
with PBS, AS monomers or oligomers for 5 min before the remain-
ing intraluminal 45Ca2+ was quantified. Ionomycin-treated micro-
somes served as positive control (Fig EV3C). No difference in
45Ca2+ efflux could be demonstrated between PBS and the AS
preparation in contrast to ionomycin that caused release of all
45Ca2+ from the microsomes. This strongly argues against AS oligo-
mers forming Ca2+-permeable pores in the biological membranes
used in our uptake assay. The Ca2+-transport cycle of SERCA
consists of several intermediary steps where dephosphorylation is
rate limiting. We studied the effect of AS oligomers on this step by
measuring the rate of breakdown of 32P-labelled SERCA after block-
ing further phosphorylation with EGTA. We thereby demonstrated
that AS oligomers stimulate the rate of dephosphorylation in
contrast to monomer and buffer control (Fig 4E). We concluded that
AS oligomers increase three functional characteristics of SERCA:
ATPase activity, transmembrane Ca2+ pumping and dephosphoryla-
tion.
To corroborate the finding that intracellular AS aggregates do,
indeed, activate ER-resident SERCA, we turned to the AS-expressing
OLN-93 model where co-expression with p25a stimulates intracellu-
lar AS aggregation [15]. OLN-T40-AS cells that stably express
human AS were used with the parental OLN-93 line without any AS
expression as negative control. ER Ca2+ levels were quantified by
the ER-targeted low-affinity Ca2+-sensing protein aequorin (erAEQ)
[25]. Cells were transfected with p25a or an empty expression
vector for 48 h, after which cellular ER Ca2+ content was depleted
by incubation with ionomycin in the EGTA-supplemented medium.
The SERCA-mediated Ca2+ uptake rate into the Ca2+-depleted ER
was determined by measuring the increase in Ca2+-dependent
aequorin luminescence after supplementing the medium with
0.5 mM Ca2+ (Fig 4F). The presence of p25a-induced AS aggregates
significantly increased the rate of ER filling compared to cells only
expressing AS. P25a expression alone did not increase uptake in ER,
but OLN-T40-AS cells displayed a greater uptake than the parental
OLN-93 cells. It is unclear whether this is due to clonal variation or
small amounts of spontaneously forming oligomers. However,
induction of AS aggregation in the OLN-t40-AS line by p25a signifi-
cantly increases ER Ca2+ uptake, supporting our hypothesis of intra-
cellular activation of SERCA by AS oligomers. To corroborate the
link between SERCA activation and the biphasic cytosolic calcium
response, we treated non-mitotic wt SH-SY5Y cells with 10 lM of
the SERCA activator XCT 790 [26] in order to mimic the AS aggre-
gate-dependent stimulation. Figure EV4A demonstrates XCT 790
caused an early reduction in cytosolic Ca2+ after 4 h followed by a
persistent increase in cytosolic Ca2+ after 24. This biphasic response
is accelerated compared to the AS aggregate-dependent response
(Fig 1B) indicating XCT 790 in this concentration is a more potent
SERCA activator than aggregated AS.
Taken together, the biochemical demonstration of AS oligomers
stimulating SERCA suggests that early reduction in cytosolic Ca2+
during AS-dependent degeneration is caused by SERCA stimulation.
We further hypothesise that early Ca2+ reduction represents a deci-
sive signalling point in the degenerative process. To test this hypoth-
esis in cells, we used the reversible SERCA inhibitor CPA [27–30].
At concentrations around 6 lM, CPA induces mild ER stress with
enhanced levels of apoptosis [31], and upon titration, we identified
the 10-fold lower 0.5 lM CPA as the minimum concentration that
could normalise the reduced Ca2+ level in non-mitotic SH-SY5Y
cells after AS expression for 5 days. This concentration did not
affect the Ca2+ levels in the b-gal-expressing control cells (Fig 5A).
The cells were treated with CPA from day 3 after transgene expres-
sion had been induced by removal of doxycycline as described for
ASI-1D treatment in Fig 1B. Surprisingly, CPA treatment by antago-
nising SERCA-dependent removal of Ca2+ from cytosol normalised
the abnormally increased cytosolic Ca2+ level in the SH-SY5Y after
10 days of transgene expression without any detrimental effects on
Ca2+ in the controls cells (Fig 5A). Normalising cytosolic Ca2+
levels by CPA treatment was beneficial because this treatment
significantly reduced AS-dependent cell loss when compared to the
b-gal expressing control cells that were unaffected by the treatment
(Fig 5B). Normalising cytosolic calcium by CPA treatment also
reduced the cell stress in the OLN-T40-AS model after 24 h expres-
sion of aggregation-inducing p25a as evidenced by an approxi-
mately 50% reduction in nuclear translocation of NF-jB) that
compares to the total reduction by treatment with the aggregation
inhibitor ASI-1D (Fig EV4B). The biphasic cytosolic Ca2+ response
in primary hippocampal neurons from AS-transgenic mice was also
normalised by CPA treatment from day 3 without affecting Ca2+
levels in cultures from wt littermates (Fig 5C). To evaluate the
protective effect of CPA treatment on the neuron cultures, we devel-
oped a survival assay based on comparing neuron numbers after 6
and 14 days of culture (Fig 5D). Because primary cultures also
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contain glial cells we used immunostaining of NeuN and MAP2 as
neuronal markers (Figs 5D and EV4C). During the period from 6 to
14 days of culture, we saw no significant reduction in non-trans-
genic primary hippocampal neurons, which contrasts with the
approximately 40% loss measured by NeuN and 30% measured by
MAP2 in the AS-expressing cultures (Figs 5D and EV4C). The CPA
treatment completely protected against AS-induced neuron loss and
had no adverse effects on the cultures of non-transgenic littermates
(Fig 5D). Treatment with 0.5 lM CPA reduced the interaction
between AS and SERCA by approx. 50% (Fig 5E) and reduced total
AS levels with 10% (Fig 5F) suggesting the reduced Ca2+ level may
compromise proteostatic mechanisms.
To test whether SERCA inhibition also is neuroprotective in vivo,
we took advantage of a C. elegans model overexpressing both AS
and GFP in dopaminergic neurons under the dat-1 promoter (Pdat-
1::GFP/AS). This model displays an AS-dependent degeneration of
anterior deirid (ADE) and cephalic (CEP) neurons compared to
C. elegans which expresses only GFP (Pdat-1::GFP) [32–34].
A B
C
E F
D
Figure 5.
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Dendrites of the 4 dopaminergic CEP neurons project towards the
anterior mouth region and are easily quantifiable by fluorescence
microscopy of fixed C. elegans [32–34]. We scored absent, discon-
tinuous and beaded dendrites as unhealthy. Examples of healthy
and unhealthy C. elegans with 4 and 1 intact dendrite are presented
in 3D-projected images in Fig 6A. Quantification of healthy CEP
dendrites of 8-day-old C. elegans is presented in Fig 6B. Control
pdat-1::GFP C. elegans displayed an age-dependent dendritic loss
with an average of 2.1 dendrites remaining. This loss is significantly
increased in AS-expressing pdat1 AS/GFP worms with only 1.5
dendrites left after 8 days (Fig 6B) representing a 40% larger loss
than in control worms. Inhibition of SERCA was initiated on 3-day-
old C. elegans by transferring them to new bacterial lawns onto
which 70 ll 10 mM CPA was evenly distributed. New CPA-covered
bacterial lawn was applied at day 6, and worms were fixed at day 8
prior to quantifying their dendrites. CPA treatment of AS-transgenic
◀ Figure 5. Inhibition of SERCA by cyclopiazonic acid normalises both the early decrease and late increase in cytosolic calcium and enhances the viability indifferentiated SH-SY5Y cells and primary neurons.
Cytosolic Ca2+ was measured by Fura-2 as described in Fig 1.
A Non-mitotic SH-SY5Y cells were treated with 0.5 lM CPA beginning after 3 days of AS/b-gal expression started using DMSO as solvent control. Bars display Ca2+
concentrations as mean  SD, N = 3 (one-way ANOVA multiple comparisons with Sidak post hoc test, *P = 0.014, **P = 0.0031, #P = 0.0254, ##P = 0.0145). The
average Ca2+ level was calculated by measuring > 200 randomly selected cells in each experiment.
B Viability of the SHSY5Y cells was measured by the MTT assay for mitochondrial oxidoreductase activity after 14 days of AS or b-gal expression with CPA (0.5 lM)
treatment from day 3. Bars represent relative viability normalised to vehicle-treated b-gal cells displayed as mean  SD. N = 3 (one-way ANOVA multiple
comparisons with Sidak post hoc test, *P = 0.0002, **P = 0.0304).
C Primary hippocampal neurons from P0 mice expressing human AS (ASO) under the mThy1 promoter and wild-type (wt) littermates were treated with 0.5 lM CPA
from day 3 in vitro (DIV 3). Cytosolic Ca2+ was measured at DIV 5 and DIV 14. Bars represent Ca2+ concentrations as mean  SD, N = 3 (one-way ANOVA multiple
comparisons with Sidak post hoc test, *P = 0.0041, **P = 0.0095, #P = 0.0081, ##P = 0.0461). The average Ca2+ level was calculated by measuring > 500 randomly
selected neurons in each experiment.
D Survival of neurons from day 6 to day 14 was quantified by counting NeuN-positive nuclei. Bars represent remaining Neu+ neurons at day 14 normalised to the
number present at day 6, presented as means  SD of four individual experiments with > 400 neurons (one-way ANOVA multiple comparisons with Sidak post hoc
test, *P = 0.0033, **P = 0.0137).
E To test the effect of CPA treatment on the interaction between SERCA and AS aggregates, non-mitotic SH-SY5Y cells expressing AS for 5 days were treated with
0.5 lM CPA during the last 2 days. The cells were subjected to AS-SERCA PLA using SERCA2 and syn211 as antibody pair as described in Fig 3. The total red
fluorescence signal from the PLA was divided by the DAPI signal to normalise for cellular content. In each experiment, 10 microscopic images containing > 100 cells
were quantified. Data are presented as normalised to the signal from non-CPA-treated cells. Bars represent mean  SD signal normalised to AS-expressing cells from
three experiments (one-way ANOVA multiple comparisons with Sidak post hoc test *P = 0.0001).
F a-syn levels in differentiated SH-SY5Y cells expressing a-syn for 5 days, and treated the last 2 days with 20 lM ASI-1D or 0.5 lM CPA, were measured by
immunoblotting. Representative immunoblot is presented. Quantification of a-syn normalised to the actin loading control is presented as geometric mean  95% CI
for six independent experiments (Wilcoxon signed rank test, *P = 0.0313).
A B
Figure 6. Inhibition of SERCA by cyclopiazonic acid protects against human AS stress-dependent loss of dopaminergic neurons in C. elegans.
C. elegans expressing human AS in dopaminergic neurons was used to test the neuroprotective role of SERCA inhibition in vivo. C. elegans (Pdat-1::GFP/AS) overexpressing both
human AS and GFP under the dat-1 promoter was compared to C. elegans (Pdat-1::GFP) expressing GFP alone, and neurodegeneration was evaluated by quantifying the
dendritic projection to the mouth region from the four dopaminergic cephalic (CEP) neurons in the anterior region of C. elegans.
A Representation of an 8-day-old Pdat-1::GFP worm with four intact CEP neurons determined by the presence of intact anterior projecting dendrites (left) and an 8-day-
old Pdat-1::GFP/AS worm with one remaining dendrite (right). Images are 3D reconstructions of z-stacks obtained at 63× magnification. Scale bar is 20 lm.
B Quantification of average number of intact CEP neurons per C. elegans upon CPA treatment. CPA treatment of C. elegans started at day 3. Bars represent the average
number of healthy dendrites projecting from CEP neurons  SD. N = 4 (one-way ANOVA multiple comparisons with Sidak post hoc test, *P = 0.0146, **P = 0.0008).
> 35 worms per experiment.
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worms rescued survival of CEP neurons to the level seen in control
worms, but did not affect age-dependent CEP loss in control
C. elegans (Fig 6B). This indicates that SERCA inhibition by CPA
specifically rescues the AS-dependent, but not age-dependent,
dendrite loss which supports the hypothesis of SERCA inhibition as
a therapeutic strategy in a-synucleinopathies (Fig 8).
To investigate if AS and SERCA interact in human brain, we
conducted the AS-SERCA PLA assay on brain sections of occipital
cortex from a neurological intact control patient and frontal cortex
from a patient affected by DLB (Fig 7A and B). Inspection of images
captured from the control patient revealed a low level of PLA-
positive signals that always were present as single spots or a few in
proximity. By contrast, the DLB patient displayed a large number of
labelled cells that often possessed clusters of many PLA signals
indicative of larger amounts of complexes in individual cells. This
was evident by the significantly increased area covered by PLA
signals and also the increased intensity of the signals (Fig 7B). It
should be noted that there is a large variation in the amount of PLA
signals within DLB tissue suggesting the disease process is heteroge-
neously affecting the tissue being studied.
The hallmark glial cytoplasmic inclusions (GCI) in MSA presents
with insoluble AS fibrils in oligodendroglia. We investigated
whether SERCA cosegregates with insoluble AS fibrils in cerebellar
extracts from three cases diagnosed with MSA and compared them
to three neurological healthy cases (control) where is expected to be
detergent soluble. Figure 7C demonstrates the presence of SERCA
along with AS in the detergent-insoluble fractions in MSA cases
whereas this fraction i in the control cases was devoid of SERCA
and AS. This contrasts the total homogenates that displayed similar
amounts of SDS-extractable SERCA.
To further investigate the association of SERCA to insoluble AS
fibrils in Lewy bodies (LB) and GCI we isolated from the midbrain
of a PD patient and glial cytoplasmic inclusions (GCI) from temporal
white matter of an MSA patient. We used this purified preparation
because they are rich in AS aggregates and devoid of the strong
ubiquitous staining that arises from ER present in all brain cells.
Immunofluorescence microscopical analysis revealed SERCA
epitopes in both midbrain LB and MSA-derived GCI (Fig 7D and F).
In LBs, SERCA is present as large granular structures in the core
where AS is less abundant, whereas SERCA in GCI displays a more
even and less granular presence largely co-localising with AS
(Fig 7D and F). We also stained inclusions for the ER protein GRP78
(also known as BiP) to evaluate if the SERCA protein may be
embedded in ER when present in the AS-containing inclusion
(Fig 7E and G) and could confirm GRP78 is present in both types of
inclusions.
Discussion
To the best of our knowledge, we are the first to demonstrate a
prolonged cellular state characterised by a reduced level of cytosolic
Ca2+ in neurons elicited by a progressive build-up of intracellular
AS aggregates. The reduced Ca2+ level is observed in cell models at
an early stage of the degenerative process where cells appear unaf-
fected. Quantitatively, it amounts to an approximately 20% reduc-
tion in the resting level in primary hippocampal neurons from 150
to 125 nM. Our observation is corroborated by an X-ray
fluorescence study that observed a reduced amount of Ca2+ in
frozen cultured neurons expressing transgenic human AS, albeit this
analysis did not allow for specific assignment of the reduced Ca2+
to cytosol [35]. The apparently unaffected or “healthy” phenotype
at this early stage may be the reason for the phase staying unrecog-
nised, but another reason is that studies of AS in relation to Ca2+
have focussed on dynamic effects like Ca2+-influx induced by depo-
larisation or effects of applying extracellular AS on stimulation by
neurotransmitters [36,37]. The significance of an early degenerative
phase was first noted in our OLN cell model [15], where the expres-
sion of certain genes was increased early after induction of AS
aggregation, which is where we observe decreased cytosolic Ca2+
[10]. Silencing one of these genes protected the cells and motivated
us to study this phase in more depth [10]. Increases in cytosolic
Ca2+ can be considered a cellular default response to a range of
noxious stimuli that compromises the active and coordinated ion
transport processes maintaining the steep gradient of Ca2+ ions
across membranes. Such increases are hypothesised to represent
pathogenic drivers in a range of neurodegenerative states like AD
and PD [38,39].
Apart from the study of Ramonet et al, where the cation ATPase,
ATP13A2 encoded by PARK9 gene was overexpressed in mouse
cortical neurons [40], reduced cytosolic Ca2+ for prolonged periods
has not been observed in known disease models. However, this can
be obtained for limited periods of time by infusion of Ca2+ chela-
tors, for example BAPTA, through patch pipettes that elicit acute
electrophysiological effects [41,42]. Increased expression of Ca2+-
binding proteins has been used to lower Ca2+ levels, but this strat-
egy is not optimal for lowering steady-state Ca2+ levels. However, it
allows changing of Ca2+ transients, for example in the study of the
effect of glutamate on Ca2+-dependent genes by nuclear targeting of
Ca2+-buffering parvalbumin [43]. The reduction of cytosolic Ca2+
by intracellular AS aggregates comes at the cost of energy as Ca2+
has to be actively transported. Mechanistically, this process can be
facilitated by ion exchangers like sodium–Ca2+ exchanger (NCX) or
by Ca2+ pumps. The low basal cytosolic Ca2+ level in our models
suggests that high-affinity mechanisms are operating in contrast to
low affinity but high-capacity NCX transporters. Ca2+ pumps are
optimal for this process as they have evolved to fine-tune cytosolic
Ca2+ levels in the nanomolar range [44–46]. We hypothesised that
aggregated AS binds directly to and stimulates the predominant
Ca2+ pumps in the plasma membrane and endoplasmic reticulum,
PMCA and SERCA, because total AS levels remain fairly stable in
our cell models and the decrease in cytosolic Ca2+ is prevented by
the aggregation inhibitor ASI-1D. Co-immunoprecipitation experi-
ments followed by proteomic techniques have demonstrated that
PMCA from porcine brain binds both monomer and oligomeric AS
[20]. Likewise, SERCA was found to bind AS by pull-down experi-
ments; however, pronounced selectivity was seen with strong bind-
ing of aggregated AS to SERCA in contrast to very low binding of
monomeric AS. The interaction seems to rely on specific structural
features of SERCA because the Ca2+-bound E1 state demonstrated
stronger interaction with AS than the Ca2+-free thapsigargin-stabi-
lised E2 state. During the E1-E2 transition, the largest structural
change in the cytosolic part of SERCA occurs in the actuator domain
[47,48], suggesting that this region may be a candidate for binding
AS aggregates. The binding of AS oligomers to SERCA resulted in
activation of three functional characteristics: Ca2+ pumping, ATP
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hydrolysis and SERCA dephosphorylation. This suggests that AS
aggregates bind to a defined part of SERCA that promotes its overall
functionality. In fact, the actuator domain undergoes major
structural rearrangements during the E1P-E2P-E2 partial reaction
steps involved in dephosphorylation [49], and this reaction
sequence is rate limiting for Ca2+ pumping and ATP hydrolysis. It is
A C
B
D F
G
E
Figure 7. AS and SERCA co-occur in synucleinopathies.
A Representative image of proximity ligation assay using SERCA2 and syn211 as antibody pair on 5-lm sections paraffin-embedded human frontal cortex from DLB
case (DLB) and occipital cortex from neurological healthy case (Ctrl). Scale bar is 20 lm.
B The proximity ligation signal was quantified in 10 randomly distributed microscopic images using ImageJ as mean area  SD covered by PLA signal (left graph) and
mean PLA intensity  SD in the covered area (right graph) of signal above 3× the background signal (Student’s t-test, *P = 0.0023, **P = 0.0011).
C Immunoblot analysis of extracts from human cerebellar dentate nucleus from three neurological healthy cases (Control) and three cases with multiple system
atrophy (MSA). Presented is the total homogenate and the detergent-insoluble fraction solubilised in 5% SDS, 8 M urea prior to immonoblotting analysis (detergent
insoluble). The molecular markers for the individual immunoblots are presented to the right of the panels.
D Immunostaining of isolated Lewy body (LB) from a PD patient labelled for AS and SERCA2 immunoreactivity. Scale bar is 5 lm.
E Immunostaining of isolated LB from a patient with DLB labelled for AS and ER marker GRP78. GRP78 reactivity is present in the inclusion. Scale bar is 7.5 lm.
F Immunostaining of isolated glial cytoplasmic inclusion (GCI) from MSA patient labelled for AS and SERCA. DAPI stains a co-isolated oligodendrocyte nucleus. Scale bar
is 5 lm.
G Immunostaining of isolated GCI from MSA patient labelled for AS and GRP78. Scale bar is 7.5 lm.
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thus plausible that interaction of AS aggregates with the actuator
domain activates Ca2+ pumping and ATP hydrolysis by facilitating
the E1P-E2P-E2 steps. The existence of protein-based regulators of
SERCA pumps is not unprecedented. Under normal conditions,
SERCA activity is inhibited by phospholamban for SERCA1 and -2
[22] and sarcolipin for SERCA1 in skeletal muscle [50]. In contrast,
presenilin-1 and -2 have been shown to activate SERCA2b [51], link-
ing SERCA activation to Alzheimer’s disease. We studied SERCA1a
in most biochemical assays. However, to exclude that the AS
oligomer interaction with SERCA studied relies on muscle-specific
SERCA properties, we also demonstrated that oligomers stimulate
human SERCA1a from microsomes of COS-1 cells overexpressing
human SERCA1a and that they bind to SERCA protein in extracts
from mouse and porcine brains as determined by immunoprecipita-
tion.
The soluble oligomeric AS aggregates used for binding and func-
tional studies are chemically unmodified [52] in contrast to other
in vitro produced oligomers that rely on chemical modifications
[53,54]. Our oligomers display a folding pattern that differs from
insoluble filaments based on HDX-MS investigations [19], but share
functional properties with amyloid-type AS filaments like inhibition
of 20S proteasomes [21], binding of aggregate-specific antibody
FILA-1 [55] and stimulations of SERCA activity (Fig 4B). To visu-
alise the oligomers, we immobilised them on EM grids immediately
upon their elution from the gel filtration column. The oligomers
displayed an underlying structure of twisted ribbons with a
tendency to form closed and open circular structures with a diame-
ter of around 40 nm. These structures resembled the annular struc-
tures formed between wild-type and A53T mutant AS that display a
diameter in the 50 nm range and with regular height fluctuations
[56]. Our oligomer preparation displays greater structural resolution
than those previously reported [52,56]. The reason may be our rapid
immobilisation on the EM grid, which contrasts with previous stud-
ies where samples were stored at 4°C for varying stretches of time
before analysis by TEM and analytical ultracentrifugation [52,56].
Low temperatures may adversely affect structural studies of AS
oligomers because they dissociate into monomers at 4°C with 15%
released after 3 h and 95% after 14 days along with loss of epitopes
for conformational-specific antibody FILA-1 [19]; and further cool-
ing to 13°C dissociates even stable amyloid AS fibrils [57]. Our
well-characterised oligomer preparation will form a good starting
point for generating complexes with purified SERCA for analysis by
high-resolution single particle cryo-electron microscopy [58], as
such complexes will allow the characterisation of the interphase
between the well-characterised SERCA surface and the active
surface of the yet uncharacterised AS oligomers. Insoluble fragments
of AS filaments may also be used for such studies because they
engage SERCA and activate its ATPase activity, but are easier to
generate and are more stable than oligomers. AS oligomers have
been proposed to function as pores in biological membranes [59–
61]. However, most of these reports are based on studies of artificial
phospholipid membranes and use high concentrations of oligomers.
We recently demonstrated that our AS oligomer preparation is toxic
to OLN-93 cells when applied at 70 lg/ml [62]. However, only 15%
of the cells died within 24 h, indicating the toxicity was not based
on formation of non-specific pores in plasma membranes, but rather
caused a stress-triggering toxic response from within the cell, for
example by Ca2+ entering voltage-gated Ca2+ channels [37]. We
tested directly if our AS oligomer preparation permeates the micro-
somes used for the 45Ca2+ uptake assay at concentrations of 50 lg/
ml and found no increased 45Ca2+ efflux from preloaded micro-
somes treated with oligomers compared to monomers or buffer
(Fig EV3C). We therefore feel confident that the oligomer-stimulated
45Ca2+ uptake is due to SERCA activation.
The specific SERCA inhibitor CPA can antagonise SERCA activa-
tion and was used to investigate the significance of the reduced
cytosolic Ca2+. Dose–response experiments demonstrated that
chronic treatment with 0.5 lM CPA abrogated the early reduction in
cytosolic Ca2+ observed in cell models and primary neurons and
prevented subsequent Ca2+ increase and ensuing AS aggregation-
dependent cell death. The effective CPA concentration of 0.5 nM
was low compared to what is used to induce unfolded protein stress
in cell models [63,64], and it was not toxic to our cell models even
after treatment for more than 2 weeks. This was expected because
low-dose long-term pharmacological inhibition of SERCA with thap-
sigargin that causes a sustained increase in cytosolic Ca2+ protects
against neuronal cell death due to growth factor removal [65]. The
prevention of the later phase with increased cytosolic Ca2+ is
surprising because CPA acts by preventing SERCA pumping Ca2+
from cytosol into ER which should thus favour an increase in
Figure 8. AS aggregates stimulate SERCA activity leading to reduced
cytosolic Ca2+ and neuron dysfunction and death.
AS aggregates bind and stimulate the active SERCA-mediated transport of
cytosolic Ca2+ into the endoplasmic reticulum. During the building-up process of
cytosolic AS aggregates, the stimulation of SERCA causes an early reduction in
cytosolic Ca2+, increased ER Ca2+ that could lead to increasedmitochondrial Ca2+.
The dysregulated Ca2+ perturbs Ca2+-dependent processes, leading to
progressive neuronal dysfunctions. Ultimately, compensatory mechanisms fail,
whereafter cytosolic Ca2+ rise and the neurons die. Inhibition of AS aggregation
by the inhibitor ASI-1D and reducing the activity of SERCA by its inhibitor CPA
counteracts the Ca2+ dysregulation and protect the neurons.
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cytosolic Ca2+. This suggests that the secondary Ca2+ increase
represents a breakdown of compensatory processes leading to an
unbalanced influx from Ca2+ stores, for example enhanced efflux
from ER due to sensitisation of ryanodine or inositol-1,4,5 tris-phos-
phate receptors, Ca2+ channels or from extracellular space via
dysregulated Ca2+ influx channels or exchangers. The protective
effect of CPA demonstrates that pivotal degenerative processes are
activated during the early phase are amenable to pharmacological
intervention. Their nature remains largely unknown but the stress
that elicits the cytoprotective NF-jB AS aggregates [10] is reduced
in our OLN model upon inhibition of SERCA by CPA (Fig EV4B).
NF-jB is increased in PD as determined by accumulation of p65 in
midbrain dopaminergic neurons and Lewy body inclusions in PD
and DLB [66–70] and it is also activated by disease-causing muta-
tions in LRRK-2 when studied in iPSC-derived neurons [71]. Inhibit-
ing NF-jB signalling in c-REL-deficient mice induces a late onset
parkinsonism also comprising accumulation of aggregated AS [72]
and the NF-jB inhibitor IjBia is increased early in anterior cingulate
in PD [73] like we demonstrate in our cell model [10]. This suggests
protective NF-jB signalling may be of particular importance for the
nerve cell populations being vulnerable in PD.
The reduced Ca2+ levels do also directly affect the cellular hand-
ling of AS as demonstrated by CPA treatment reducing the interac-
tion between AS aggregates and SERCA by PLA assay and lowering
levels of total cellular AS suggesting involvement of chaperone and
protein catabolic pathways (Fig 5E and F). How this mechanistically
is carried out is uncertain. Several investigations have studied direct
effects of Ca2+ on AS aggregation in vitro. They demonstrate a
proaggregatory effect of increased Ca2+ levels but often with fluo-
rescently labelled AS proteins [74] and those using non-modified
proteins used high Ca2+ concentrations [23] because the C-terminal
Ca2+-binding site in AS has an IC50 around 200 lM) [75]. However,
changed Ca2+ levels have potential for affecting a range of pathways
regulating intracellular AS levels and specific candidates for rescue
by CPA treatment are chaperone-mediated autophagy [76], USP-19-
dependent excretion of aggregated AS [77] and changed gene
expression regulating cytoprotective so-called neuroprotective shield
genes that depend on nuclear Ca2+ concentration [43]. The neuro-
protective effect of CPA against AS aggregate toxicity and thapsi-
gargin against growth factor withdrawal-dependent neuron death
[65] demonstrates that SERCA represents a potentially neuroprotec-
tive target, but its ubiquitous expression raises concerns regarding
adverse effects in other organ systems. However, there is prece-
dence for targeting ubiquitously expressed ion transporting ATPases
as exemplified by the cardiotonic steroids targeting Na-K-ATPase,
which is used in congestive heart failure with a narrow therapeutic
window [78,79]. Importantly, structural studies of the interaction
between AS aggregates and SERCA may allow identification of
compounds that block this abnormal interaction. In principle, such
compounds could target surfaces of the AS aggregate. Although the
active surfaces of AS aggregates are unknown, we show that AS
requires C-terminal 45 residues in its monomeric building blocks as
demonstrated by absent stimulatory activity of filaments formed by
C-terminally truncated AS-1-95. This is analogous to what was
required to exhibit increased AS aggregate affinity towards p25a
protein [21]. This highly negatively charged and proline-rich region
of AS has never been resolved in structural studies and the recently
described Greek-key type beta-sheet domain resolved in AS
filaments terminated around residue 98 [80], so it remains unknown
how it contributes to aggregate-dependent functions. Rather than
targeting SERCA and AS aggregates, more tractable down-stream
targets may be uncovered by studying the degenerative signalling
pathways activated during the early low-Ca2+ phase, for example
protective nuclear NFkB translocation that is attenuated upon CPA
treatment (Fig EV4B). Such AS aggregate-dependent dysfunctions
may radiate from the endoplasmic reticulum, as this organelle
contributes to a multitude of cellular functions including protein
sorting, unfolded protein response, excretion of misfolded cytosolic
proteins during proteasomal stress, uptake of Ca2+ via store-
operated Ca2+ entry from the plasma membrane and Ca2+ loading
into mitochondria via mitochondria-associated membranes (MAMS)
[81]. The endoplasmic reticulum permeates all neuronal compart-
ments from pre- to post-synaptic structures, and AS aggregates
appear to have a preference for targeting endoplasmic reticulum in
AS-transgenic mouse and PD brain tissue [17]. The SERCA affinity
of oligomers can represent one mechanism whereby they become
concentrated at the ER surface, and the activation of its Ca2+ trans-
porting activity can affect ER functions including protein folding and
Ca2+ signalling, for example via ligand-gated ryanodine or inositol-
1,4,5 tris-phosphate Ca2+ channels. We demonstrate the SERCA
activator XCT 790 qualitatively can mimic the AS aggregate effect by
first causing a reduction in cytosolic Ca2+ that subsequently is
followed by an increased Ca2+ level that likely reflects a breakdown
of compensatory mechanisms (Fig EV4A). Although the biphasic
process caused by 10 lM XCT 790 is accelerated, does it suggest
that studies of cellular responses to SERCA activators may be used
to disentangle the complex response induced by intracellular AS
aggregates and which may arise from several AS aggregate-induced
dysfunctions, for example caused by low Ca2+ stress, ER overload
stress, mitochondrial stress and dysfunctional autophagy.
The duration of the period where a neuron encounters reduced
average cytosolic Ca2+ will likely influence its contribution to the
symptomatology of synucleinopathies where the effect of neuronal
dysfunction on circuitries may differ from a frank loss of the cell. In
the non-mitotic SH-SY5Y model, cells exhibit progressive degenera-
tion where approximately 30% of the cells are lost after 14 days in
accordance with previous reports [13]. These cells experienced
reduced Ca2+ for 6 days of the 2 weeks period, which is a signifi-
cant part of these non-mitotic cells’ life span. According to the Braak
hypothesis of prion-like spreading of misfolded AS cytopathology,
individual neurons likely encounter a gradual build-up of patho-
genic AS species that may last for years before the cells ultimately
die. In this process, they may have passed on prion-like AS species
to connected neurons and contributed to symptomatology by chang-
ing circuitry properties that are modulated by low cytosolic Ca2+.
The hypothesis of prion-like spreading of AS cytopathology in the
nervous system posits that small amounts of misfolded AS seeds are
released from donor cells and taken up in recipient cells. Here, they
start a process of templated aggregation of the native AS that would
result in a gradual build-up of intracellular aggregates that may span
from early oligomeric species to mature amyloid-type fibrils. The
time-course for this build-up is unknown, but it can be obtained in
transgenic mouse models by inoculation of preformed fibrils or
brain extracts from diseased animals, which initiate a neurodegener-
ative process that traverse several neurons within months [82]. In
humans, the process is expected to be much slower. In relation to
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the Braak staging of PD, RBD is hypothesised as representing early
manifestation with LB development in brainstem regions preceding
the spread to midbrain dopaminergic neurons where actual parkin-
sonism evolve [83]. More than 70% of RBD patients develop PD
within 7 years, which suggests that migration of symptom-causing
misfolded AS species from the lower brainstem to the midbrain can
take several years. To investigate the hypothesis that AS aggregate-
dependent effects on SERCA may occur in brain regions not
commonly recognised as affected by Lewy body pathology, we stud-
ied the frontal cortex from a DLB patient and occipital cortex from
an age-matched control using the AS-SERCA PLA assay. Figure 7A
and B demonstrates nearly absent signals in the controls brain
suggesting no interactions between SERCA and AS aggregates are
taking place. By contrast, the DBL brain exhibits strongly increased
signal in terms of area covered with PLA signal and intensity of the
signals. This strongly corroborates our hypothesis that interactions
between SERCA and AS aggregates develop in tissue from patient
affected by synucleinopathies. Our data merely serve as proof of
concept, but will justify proper clinical studies of selected brain
regions from larger patient cohorts affected by different synucle-
inopathies. The large microheterogeneity observed in the AS-SERCA
PLA signal on the stained tissue section calls for further studies in
affected cell types and their relation to putative structural dif-
ferences and tissue responses like neuroinflammation (Fig 7B). To
further substantiate the interaction between aggregated AS species
and SERCA, we analysed the extracts from the cerebellar dentate
nucleus from three MSA patients and three controls. The tissue was
subjected to differential extraction to investigate if the normally
detergent-soluble SERCA in the MSA cases will co-fractionate with
the detergent-insoluble AS aggregates. Figure 7C demonstrates the
presence of detergent-insoluble AS in the MSA cases in contrast to
the controls and SERCA cosediment with the insoluble AS aggre-
gates. To further describe the relation between aggregated AS and
SERCA within the AS fibrils intracellular inclusions, we isolated
Lewy bodies from patients affected by PD and DLB and also GCI
from a patient affected by MSA. SERCA was preferentially present in
the core of the brainstem-type Lewy bodies from the PD patient
whereas it was more diffusely distributed along with the fibrillar AS
in the less well organised DLB-type Lewy bodies and the GCI. In the
inclusions, SERCA colocalised with the ER marker, Grp78, suggest-
ing ER structures may be trapped in the inclusions, which may
contribute to ER dysfunctions.
How may these experimental findings reconcile with first previ-
ous epidemiological and genetic data on protective effects against
PD by L-type Ca2+ channel antagonists [2,3] and second the
pathoanatomical data on selective vulnerability of neuronal popula-
tions in PD that in substantia nigra pars compacta neurons exhibit
large Ca2+ driven by L-type Ca2+ channels [84,85]? First, it should
be kept in mind that both the early phase with reduced cytosolic
Ca2+ and the following phase with increased Ca2+ both are inhib-
ited by inhibiting SERCA with CPA. Hence, treatment strategies
targeting the high Ca2+ phase may still contribute some cellular
relief despite not targeting the underlying mechanism. The largest
epidemiological study confirmed a protective effect of ongoing
treatment with L-type Ca2+ channel antagonists but there was no
effect of past use, which made the authors suggest the effect could
represent a symptomatic relief rather than a true disease
modification [3].
In our proposed paradigm of a biphasic basal Ca2+ change in
neurons experiencing a build-up of AS aggregates, L-type Ca2+
channel antagonists may retard or attenuate the second phase with
increased cytosolic Ca2+ that is associated with development of cell
death. An action on the early phase can also be envisioned if expres-
sion of CaV1.3 channels partly is regulated by negative feedback
from average cytosolic calcium levels. The increased levels of
CaV1.3 antigen and mRNA in cortical tissue with no Lewy body
pathology from early PD patients [4,5] could represent a response to
soluble AS oligomers activating SERCA and reducing average Ca2+
in neurons not exhibiting spontaneous pace making changes in
Ca2+ as in dopaminergic neurons of substantia nigra pars compacta.
The ongoing clinical study of early PD patients treated with L-type
Ca channel antagonist isradipine may inform about these issues in
the near future (ClinicalTrials.gov Identifier: NCT02168842).
The selective vulnerability of neuronal populations lost in PD has
allowed certain characteristics of these neurons to be proposed [84].
Areas affected by Lewy body pathology and substantial neuron loss
in PD can be exemplified by substantia nigra pars compacta, locus
coeruleus, median raphe nucleus. These neuronal populations
display diffuse axonal projections and often possess very large
numbers of presynaptic terminals [84]. AS is a protein that normally
resides in presynapses in high concentrations and its aggregation
process is concentration dependent. This makes presynapses likely
to be the first sites to experience the build-up of AS aggregates, as
supported by proteinase K blotting experiments on cortical tissue
affected by dementia with Lewy bodies [86], that secondarily will
activate SERCA, increase ATP consumption and reduce cytosolic
calcium levels at these sites. A local aggregatory process in terminals
may spread within the terminal field of individual neurons as AS
readily disperses between terminals of single neurons in a process
affected by neuronal activity [87]. The engagement of SERCA pumps
in the large terminal fields of vulnerable neurons will increase ATP
consumption putting a stress on their mitochondria and the poten-
tially increase oxidative stress. This process be further complicated
because the reduced average cytosolic Ca2+ may compromise activ-
ity-dependent calcium loading into mitochondria thereby compro-
mising their oxidative phosphorylation [88]. When aggregation
increases and AS aggregates are transported from terminals into
axons and cell bodies then different mechanisms may come into play
caused by the SERCA activation both due to lowered calcium, for
example in the nucleus [89] and potentially also ER Ca2+ overload if
not relieved by overload channels [90]. How these mechanisms
driven by a reduced average cytosolic Ca2+ interacts with cell type-
specific effects in vulnerable substantia nigra dopaminergic neurons
will have to be tested? They may affect the Ca2+-induced Ca2+-
release from ER facilitated by the oscillating in Ca2+ driven by the
L-type Ca2+ channels and thereby the well-described filling of Ca2+
into mitochondria [91]. However, the recently described ER overload
channel TMCO1 may well add another layer of complexity in condi-
tions where SERCA activation will cause Ca2+ overload in ER [90].
However, irrespective of vulnerable areas in PD it should be kept in
mind that AS aggregate pathology has potential to affects brain cells
on a broader scale. This has been demonstrated by the clinical stud-
ies of families with triplications in the SNCA gene that express
increased levels of normal AS protein as reviewed [92]. These fami-
lies often presented with parkinsonism caused by degeneration of
the vulnerable substantia nigra pars compacta but often displayed
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dementia and other non-motor symptoms at the time of diagnosis or
shortly after. This was due to widespread accumulation of aggre-
gated AS in neurons but also glial cells.
Conclusively our demonstration of AS aggregates activating
SERCA and causing dysregulation of cytosolic Ca2+ holds potential
for affecting the above-described PD-associated mechanisms apart
from yet undescribed neuronal functions that potentially are tract-
able (Fig 8). The specific nature of such dysfunctions, their signal-
ling pathways and brain regions affected in the different
synucleinopathies merits further investigations.
Materials and Methods
Cell culture and assays
OLN-T40-AS cells [93,94] were transfected with pcDNA3.1 zeo()
plasmid-expressing AS aggregation-promoting protein, p25a and
TdTomato as transfection marker, or mock control (empty vector)
[10,15,21,95] by either electroporation by AMAXA NucleofectorII
Kit L using pre-set program A-033 (Life Technologies), or FuGENE
6 Transfection Reagent (Promega) according to the manufacturer’s
instructions. SH-SY5Y cells with inducible expression of AS and b-
galactosidase (b-gal) were kind gifts from Professors Leonidas
Stefani and Kostas Vekrellis [13]. Cells were differentiated using
20 lM all-trans retinoic acid (Molecular Probes/Invitrogen) for
2 days prior to expression of AS and b-gal, which were induced by
removal of doxycycline. Primary hippocampal neurons were
cultured from new-born wt and Thy1-a-Syn Line 61 (ASO [96]) mice
(P0) [97]. Male ASO neurons were compared to neurons prepared
from wild-type males from same litter. Neurons isolated from male
pubs were only used, due to transgene insertion into X-chromosome
and to random X-chromosome inactivation in females. Hippocampi
were dissected in ice-cold Hank’s balanced salt solution, dissociated
in 20 U/ml papain in Leibovitz’s L15 medium (L15, Gibco) for
20 min at 37°C, washed twice in L15 medium and titurated in plat-
ing medium [MEM (Gibco) supplemented with 5 g/l glucose, 0.2 g/l
NaHCO3, 0.1 g/l transferrin, 0.25 g/l insulin, 0.3 g/l L-glutamine
and 10% foetal bovine calf serum (heat-inactivated)]. Hippocampal
neurons were seeded on Matrigel matrix (Corning )-coated
coverslips. After 24 h, the medium was changed to growth medium
[MEM supplemented with 5 g/l glucose, 0.2 g/l NaHCO3, 0.1 g/l
Transferrin, 0.3 g/l L-glutamine, 1× B-27 supplement, 2 lM cytosine
arabinoside and 5% foetal bovine calf serum (heat-inactivated)].
Primary neurons were genotyped for transgenic AS and gender using
the primers ASO-sense: 50-GACGGGTGTGACAGCAGTAGCC-30, ASO-
antisense: 50-GATGATGGCATGCAGCACTGG-30 and SRY F: 50-TTG
TCTAGAGAGCATGGAGGGCCATGTCAA-30, SRY R: 50-CCACTCCT
CTGTGACACTTTAGCCCTCCGA-30. Neurons and cell lines were kept
at 37°C under 5% CO2, and cell lines were tested for mycoplasma
every month. Cells and neurons were treated with either 20 lM aggre-
gation inhibitor ASI-1D (> 98% pure H-RGGAVVTGRRRRRR-NH2
(Schafer-N, Copenhagen, DK), 10 mM stock in 98% ethanol [16]) or
0.5 lM CPA (Sigma-Aldrich, #C1530, 10 mM stock in DMSO).
The viability of SH-SY5Y cells was evaluated by metabolic activ-
ity in an MTT assay (Life Technologies). Viability of primary
hippocampal neurons was evaluated as the ratio of NeuN-positive
immunostained neuronal nuclei between DIV 14 and DIV 6 or ratio
of Map-2 immunostained neuronal cell bodies between DIV 14 and
DIV 6. Images were obtained using a Zeiss Observer Z1 inverted
microscope equipped with ApoTome.2. Neuronal cells were blindly
counted in ten randomly distributed fields throughout the coverslip,
> 500 neurons on three coverslips were included in each individual
experiment (total of > 1,500 neurons).
Absolute cytosolic Ca2+ levels in OLN-T40-AS, SH-SY5Y and
primary neurons were determined using the Ca2+-sensitive fluores-
cent indicator Fura-2-AM (Molecular Probes/Invitrogen) and an
Olympus Scan^R high-content fluorescence microscope equipped
with Fura-2 filters. Cells were loaded with Fura-2 in sterile filtered
HEPES-buffered saline (HBS: 20 mM HEPES, 150 mM NaCl, 5 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, pH 7.4) containing
2.5 lM Fura-2 AM, 0.04% pluronic acid, F127 for 30 min at 37°C,
5% CO2. The Fura-2-containing medium was replaced with fresh
HBS without Fura-2 and incubated additionally for 30 min. The flu-
orescence was measured on an Olympus Scan^R high-content
microscope using excitation wavelengths at 340 and 380 nm and
emission at 510 nm. The ratio of the fluorescence signal at 510 nm
upon excitation at 340 nm and excitation at 380 nm (FL_ex340/
FL_ex380) gives a relative Ca
2+ estimate independent of cell
morphology. The cytosolic Ca2+ levels in single cells were measured
by placing a region of interest (ROI) outside the nucleus. The size of
the ROI was set to be 8 lm2. For OLN cells, at least 50 transfected
cells were measured in three independent replicates. For the indu-
cible SH-SY5Y cells and primary neurons, more than 300 cells were
measured in three independent experiments. The Fura-2 ratios were
converted to molar concentration using Fura-2 Calcium Imaging
Calibration Kit (Molecular Probes, F6774), generating a standard
curve from 0 to 350 nM Ca2+.
Transport of Ca2+ into ER in cells was measured using the OLN
cell line as described in Ref. [25]. Cells were plated in a six-well plate
and after 8 h transfected by lipofectamine with 1.5 lg plasmid encod-
ing low-affinity ER-targeted aequorin (erAEQ) and 2.5 lg of p25a or
empty vector. Twenty-four hour post-transfection, cells were washed,
collected and replated on a 96-well plate. After an additional 24 h
(48 h after transfection), cells were incubated for 1.5 h at 4°C in
Krebs Ringer modified buffer (KRB: 125 mM NaCl, 5 mM KCl, 1 mM
Na3PO4, 1 mM MgSO4, 5.5 mM glucose, 20 mM HEPES, pH 7.4 at
37°C), supplemented with the 5 lM ionomycin (A23187), 600 lM
EGTA and 5 lM coelenterazine n (Invitrogen) in order to deplete ER
Ca2+ and functionally reconstitute erAEQ. Afterwards, cells were
extensively washed with KRB supplemented with 2% bovine serum
albumin and 1 mM EGTA. Refilling of the empty ER was obtained by
placing the cells in KRB supplemented with 100 lM EGTA and CaCl2
to reach the final concentration of 0.5 mM CaCl2, and the generated
light was measured in a Perkin-Elmer Envision plate reader equipped
with a two-injector unit. At the end of the experiment, a hypotonic,
Ca2+-rich, digitonin-containing solution was added to discharge the
remaining aequorin pool. Output data were analysed and calibrated
with a custom-made macro-enabled Excel workbook. ER Ca2+ uptake
speed was calculated as the first derivative using the slope excel func-
tion and smoothed for three time points.
Immunostaining
Cells were fixed in 4% paraformaldehyde for 30 min at room
temperature (RT) followed by a wash in PBS and 10 min
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permeabilisation in 0.1% Triton X-100, 50 mM glycine, 3 mM
CaCl2, 2 mM MgCl2, pH 7.4. Unspecific binding was blocked by
3% bovine serum albumin in PBS for 1 h followed by incubation
with the primary antibody for 1.5 h [anti-AS (1 lg/ml, ASY-1
[15,21]), anti-SERCA (1 lg/ml, Abcam, ab3625), anti-p65 (NF-jB)
(2.5 lg/ml, Cell Signaling Technology, (D14E12) #8242)].
Unbound antibodies were removed by washing in PBS followed
by incubation with Alexa Fluor-conjugated secondary antibodies
(Life Technologies). Unbound secondary antibodies were removed
by washing in PBS before mounting in Prolong Antifade Gold
Mountant (Life Technologies). For Duolink PLA, the previously
described ICC protocol was followed until washing after incuba-
tion with primary antibodies [anti-AS (1 lg/ml, syn211, Abcam,
ab80627) and anti-SERCA2 (1 lg/ml, Abcam, ab3625)] and
continued according to the manufacturer’s instructions with the
Duolink In Situ Red Starter Kit Mouse/Rabbit (Duolink,
Sigma-Aldrich). All PLA experiments were stained and evaluated
blinded. Human tissue used for PLA was obtained from brain
donors recruited with informed consent through a regional brain
donor programme with ethics approval from the Human Research
Ethics Committees of South Eastern Sydney Local Health District
and the Universities of Sydney and New South Wales (Sydney)
which complies with the statement of human experimentation
issued by the National Health and Medical Research Council of
Australia. Immunohistochemical stainings were conducted on
isolated LB and GCIs from fresh-frozen brains from patients
with DLB/PD and MSA as described [98–100] using anti-SERCA
(1 lg/ml, Abcam, ab3625), anti-AS (ASY-1) and anti-GRP78 (BD
Transduction LaboratoriesTM, # 610979).
C. elegans strains and culture
All C. elegans strains were maintained at 20°C on standard nematode
growth medium (NGM) plates spotted with Escherichia coli strain
OP50 as the food source. The strain UA44 [baInl1; Pdat-1::AS, Pdat-1::
GFP] expressing AS and GFP in the dopaminergic neurons was a kind
gift from the Caldwell laboratory [32–34]. The control strain BZ555
[egIs1(dat-1::GFP)] that only expresses GFP in the dopaminergic
neurons was obtained from the Caenorhabditis Genetics Center. For
the CPA treatment, 35-mm NGM plates with a fixed volume of 4 ml
media were used. About 70 ll of CPA in DMSO (10 lM) or 70 ll
DMSO as control was spotted on top of the OP50. The plates were set
aside for 4 h to allow the CPA to disperse before 30–40 three-day-old
worms were transferred to the plates. The worms were moved to fresh
plates every other day to provide fresh CPA and avoid cross-contami-
nation with progeny. Eight-day-old worms were fixed overnight at RT
in 2% paraformaldehyde, washed three times in PBS and mounted in
fluorescence-mounting media (Dako, # S302380-2). The worms were
assessed for degeneration of the dopaminergic neurons by fluores-
cence microscopy on a Zeiss Observer Z1 inverted microscope
equipped with Apotome.2. Images were obtained using Pln Apo 63×/
1.4 Oil DIC II objective as 3D-projected images of 40 z-stage sections,
each 0.3 lm thick, giving a total image depth of 12 lm.
Protein preparations
Recombinant human AS was produced as described [101]. AS
oligomers were formed by incubation of 10 mg/ml monomeric AS
on ice for 30 min, followed by gel filtration separation of oligo-
mers and monomers according to Lashuel et al [52]. A phosphor-
free elution buffer, TBS (10 mM Tris–HCl, 140 mM KCl), was
used for transmission electron microscopy and ATPase activity
assay. AS oligomers were concentrated using Amicon Ultra-15,
Ultracell-10k filter device (Millipore). The concentration of AS
oligomer was determined by bicinchoninic acid (BCA) protein
concentration assay (Pierce).
Fresh brain tissue from C57BL/6 OlaHsd (ASdel) mice, which
does not express AS, was dounce-homogenised in threefold excess
volume extraction buffer [25 mM MES, 5 mM DTT, 2 mM EDTA,
9% sucrose, Complete Mini Protease Inhibitor (Roche)] compared
to the weight of tissue and centrifuged 1,700 g at 4°C for 15 min
to remove debris and nuclei. The resulting supernatant was
further centrifuged at 100,000 g for 1 h at 4°C, and the pellet was
dounce-homogenised in an extraction buffer containing 0.5%
Triton X-100. The homogenate was centrifuged 100,000 g for 1 h
at 4°C and used as brain membrane extract for co-immunoprecipi-
tation. SERCA1a was prepared as sarcoplasmic reticuli (SR)
microsomes by deoxycholate extracts from rabbit muscle
sarcoplasmic reticuli [102,103]. Samples were stored at 80°C
and thawed on ice immediately before the experiment. The SR
microsomes were dissolved in PBS, 1% Triton X-100 for 30 min
on ice and subsequently centrifuged at 100,000 g for 1 h prior to
co-immunoprecipitation.
Human tissue was obtained with informed consent and the
experiments conformed to the principles set out in the WMA
Declaration of Helsinki and the Department of Health and Human
Services Belmont Report. Human cerebellum dentate nuclei
(~0.05 g) were dissected from frozen brain slices of three cases of
MSA and three neurological healthy cases donated from the Brain
Bank at Bispebjerg-Frederiksberg University Hospital (University
Hospital of Copenhagen, DNK; approved by the Danish Data Protec-
tion Agency, j.no. BBH-2010-06, I-suite 00971). The use of the brain
tissue was approved by the regional ethical committee of Region
Hovedstaden (DNK), journal no. H-16025210. MSA patients were
diagnosed according to the current MSA consensus guidelines [104].
Detailed neuropathological post-mortem evaluations were performed
on each MSA brain [105]. The normal controls were free of neuro-
logical disorders. The tissue was processed according to Dickson
et al [106] with minor changes. The tissue was homogenised in 20
volumes (weight/volume) PBS+ pH 7.4, supplemented with
complete protease inhibitor mix (Roche) and phosphatase inhibitors
(25 mmol/l NaF, 25 mmol/l b-glycerophosphate, 0.1 mmol/l Na-
vanadate). Debri was removed from the homogenate by centrifuga-
tion at 1,000 g for 10 min. The supernatant (S1) was diluted to a
final protein concentration of 1 mg/ml. Equal amounts of S1 were
centrifuged at 100,000 g for 1 h. The resulting pellets were washed
twice in PBS+, extracted in PBS+ with 1% Triton X-100 with 0.5%
deoxycholate and 0.1% SDS and centrifuged at 100,000 g for 1 h.
The resulting pellet was washed twice with PBS+ with 1% Triton
X-100 with 0.5% deoxycholate and 0.1% SDS, before complete
extraction in PBS+ with 8 M urea and 5% SDS.
Electron microscopy
Fresh EM samples were prepared as previously described [107].
Specimens were applied on previously glow-discharged homemade
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carbon-coated copper girds and incubated for 10 s. Subsequently,
specimens were stained three times with 1% uranyl formate solu-
tion. Raw micrographs were acquired automatically at 42,000
magnification at specimen level using the Leginon system [108]
operated on a Tecnai Spirit BioTWIN TEM at 120 kV acceleration
voltage and a Tietz 416 CMOS detector.
Co-immunoprecipitation of AS and SERCA
Detergent extract of SR microsomes from rabbit muscle was used as
the source for SERCA, and its conformations were stabilised in E1
conformation by 5 lM Ca2+ or in E2 conformation by 1 lM thapsi-
gargin (Sigma-Aldrich, # T9033). AS oligomer or monomer
(2 lg/ml) was mixed with 0.5 mg/ml ASdel mouse brain detergent
extract of membrane fraction, or 4 lg/ml SERCA 1A detergent
extract of SR microsomes from rabbit muscle t in PBS, 0.5% Triton
X-100 and incubated overnight at 4°C. AS binding (ASY-1) or control
(non-immune IgG) sepharose beads were added in 5× molar excess
compared to AS. The samples were incubated for 2 h with rotation.
Sepharose beads were isolated by centrifugation in a tabletop centri-
fuge at 800 g for 1 min and washed twice in PBS, 0.5% Triton X-100.
The bound protein was extracted in SDS Laemmli buffer without
reducing dithiothreitol for 30 min at 37°C. Extracted immunoprecipi-
tated proteins were separated on 10–16% SDS–PAGE, electroblotted
onto PVDF membranes; immunoreactivity to AS was evaluated by
anti-AS (ASY-1) and SERCA was evaluated by polyclonal rabbit anti-
SERCA (raised against the peptide of amino acid 809-827 [109], a
kind gift from Professor J.V. Møller, University of Aarhus, DK).
Functional studies of SERCA
The ATPase activity of SERCA was studied by monitoring the
release of inorganic phosphate [110]. Transport Ca2+ by SERCA was
measured as accumulation of 45Ca2+ in microsomal vesicles, which
were quenched with LaCl3 followed by capture by filtration [111].
Combined assays to simultaneously measure Ca2+-activated ATP
hydrolysis and ATP-driven Ca2+ uptake were conducted with SR
vesicles at 37°C in a medium containing 20 mM MOPS/Tris, pH 6.8,
100 mM KCl, 5 mM MgCl3, 5 mM potassium oxalate, 0.5 mM EGTA
and 0.45 mM CaCl2 (free Ca
2+ approx. 10 lM). The medium used
for Ca2+-uptake measurements also contained 45Ca2+ (approx.
0.1 MBq/ml) to trace Ca2+ accumulation in the vesicles. The reac-
tion was initiated by addition of 5 mM ATP. This system was also
used to investigate leakage of 45Ca2+ from preloaded microsomes
with the exception of the absence of oxalate. In brief, the micro-
somes were preloaded with 45Ca2+ overnight at RT and then incu-
bated at 37°C with AS, buffer or ionomycin for 5 min before
quenching by LaCl3 and capturing on filter. Furthermore, dephos-
phorylation of 32P pre-phosphorylated SERCA was followed by serial
time interval quantification of acid-quenched SERCA on SDS–PAGE
[102,111]. Pre-phosphorylation of SERCA was conducted at 0°C for
15 s in the presence of 5 lM [c-32P]ATP and 40 mM MOPS/Tris, pH
7.0, 122 mM KCl, 5 mM MgCl2, 1 mM EGTA and CaCl2 to give a
free Ca2+ concentration of 10 lM, and terminated by addition of
10 mM EGTA to chelate Ca2+. The rate of dephosphorylation was
followed over time by acid-quenching the reaction at serial time
intervals, and the phosphoenzyme in the quenched samples was
isolated by acidic SDS–PAGE and quantified using the Packard
CycloneTM storage phosphor system [111]. The dephosphorylation
rate constants were determined as mono-exponential decay function
using the SigmaPlot program (SPSS, Inc.).
Enzyme-linked immunosorbent assay
A 96-well maxisorb plate was coated with Syn211 (1 lg/ml) and
incubated for 2 h at RT. The plate was washed with TBS-T and
blocked in 10% foetal calf serum for 2 h at RT followed by incuba-
tion with 0.7 nM biotinylated AS overnight at 4°C with or without
increasing amounts of non-biotinylated AS (3.5, 7 or 35 nM) or ASI-
1D (5, 10 or 20 lM). After washing, streptavidin-conjugated HRP
was added for 2 h at RT followed by addition of TMB. The reaction
was stopped by addition of 1 M phosphoric acid, and absorbance
was measured at 450 nm.
Statistical analysis
Statistical evaluation of results was performed using parametric
tests for data sets following normal distribution by comparing
means  SD. For smaller data sets where normal distribution could
not be proven, statistical evaluation was conducted by nonparamet-
ric tests and data presented as geometric mean  95% confidence
interval. In order to compare one mean to another mean, Student’s
t-test was conducted as parametric test and Wilcoxon signed rank
test was used as nonparametric test. In order to test the null-
hypothesis in multiple comparisons, when comparing several
groups to one mean, one-way ANOVA combined with Sidak post
hoc test was applied as parametric test and Kruskal–Wallis one-way
rank test with Dunn’s post hoc test was applied as nonparametric
test to obtain an adjusted P-value using the GraphPad Prism
program (GraphPad Software). P-values below 0.05 are considered
to be statistically significant.
Expanded View for this article is available online.
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